The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000676314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
8/05/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
10/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Do vaginal probiotic supplements improve pregnancy outcomes in women having frozen embryo transfer?
Scientific title
Vaginal Probiotic Supplementation and Outcomes in Women Undergoing Frozen Embryo Transfer Cycles: A Randomised, Double-Blinded, Placebo-Controlled Trial
Additional trial identifiers [1] 317236 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
infertility 341851 0
Condition category
Condition code
Reproductive Health and Childbirth 337917 337917 0 0
Fertility including in vitro fertilisation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention:
Vaginal probiotic supplementation (Amelia V-Spot - containing 4 strains of lactobacillus)
Dose: once vaginal suppository daily (Lactobacillus crispatus 2 billion CFU, Lactobacillus rhamnosus GR-1 1.25 billion CFU, Lactobacillus reuteri RC-14 1.25 billion CFU, Lactobacillus gasseri 2 billion CFU)
Duration of treatment: approximately 2 weeks (from cessation of menses to embryo transfer)
Mode of delivery: vaginal pessary
Adherence: participant self-reporting and review at treatment visits
Intervention code [1] 334010 0
Treatment: Drugs
Description of the comparator or control
Comparitor:
Placebo in identical packaging: ingredients to be supplied by Amelia Bio (~600g microcrystalline cellulose in ~ 2,000 HPMC transparent hardshell capsule), assembled at compounding pharmacy (MIDAS healthcare), sent for microtesting (ScienTEST Analytical Services Pty Ltd) to ensure no contamination
Dose: once daily
Duration of treatment: approximately 2 weeks (from cessation of menses to embryo transfer)
Mode of delivery: vaginal pessary
Adherence: participant self-reporting and review at treatment visits
Control group
Placebo

Outcomes
Primary outcome [1] 345365 0
Clinical pregnancy test
Timepoint [1] 345365 0
Clinical pregnancy is the primary endpoint, which is defined as the presence of a pregnancy confirmed on ultrasound with a gestational sac and heartbeat, usually performed around 6-8 weeks gestation.
Secondary outcome [1] 461424 0
Miscarriage rate
Timepoint [1] 461424 0
Pregnancy loss prior to 20 weeks
Secondary outcome [2] 461425 0
Live birth - Birth of baby after 20 weeks gestation and at least 400g that shows signs of life
Timepoint [2] 461425 0
12 months after recruitment concluded
Secondary outcome [3] 461426 0
Vaginal microbiome composition
Timepoint [3] 461426 0
Vaginal swab taken cycle prior to recruitment + at time of embryo transfer
Secondary outcome [4] 461427 0
Tolerability
Timepoint [4] 461427 0
Checked verbally at each encounter, survey at conclusion of study
Secondary outcome [5] 461897 0
Participant satisfaction
Timepoint [5] 461897 0
Survey at conclusion of study

Eligibility
Key inclusion criteria
• Women with infertility
• Age < 45 years age
• Attending for a FET cycle with a single euploid embryo
• Willing to provide informed consent, willing to participate and comply with study requirements
Minimum age
No limit
Maximum age
45 Years
Sex
Females
Healthy volunteers
No
Key exclusion criteria
• Recurrent implantation failure (= 3 consecutive implantation failures)
• Known uterine anomaly or genetic condition
• Symptomatic with vaginal infection
• Oral or vaginal probiotic use
• Oral antibiotic use at commencement of cycle
• Allergy or hypersensitivity to suppository ingredients (lactose, maltodextrin, sodium ascorbate, sucrose, microcrystalline cellulose, magnesium stearate, colloidal silicone anhydrous, maltose)
• Circumstances/conditions which may interfere with the participant’s ability to give informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will be achieved through central computer-generated randomisation. Sequentially numbered identical probiotic and placebo treatment packs will be prepared and labelled by an independent party not involved in participant recruitment, treatment, or outcome assessment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The allocation sequence will be generated using REDCap by a statistician independent to the study and kept from participants, clinicians, investigators and embryologists. Randomisation will be 1:1 to either treatment with Amelia V Spot Probiotic or an identically packaged placebo. The manufacturer will be informed to mark the products using the placebo allocation sequence.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321814 0
Commercial sector/Industry
Name [1] 321814 0
Amelia Bio
Country [1] 321814 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Genea Fertility
Address
Country
Australia
Secondary sponsor category [1] 324666 0
None
Name [1] 324666 0
Address [1] 324666 0
Country [1] 324666 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320358 0
Genea Ethics Committee
Ethics committee address [1] 320358 0
Ethics committee country [1] 320358 0
Australia
Date submitted for ethics approval [1] 320358 0
07/05/2026
Approval date [1] 320358 0
Ethics approval number [1] 320358 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150210 0
Dr Cathy Liu
Address 150210 0
Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, 3052, VIC
Country 150210 0
Australia
Phone 150210 0
+61 0383453200
Fax 150210 0
Email 150210 0
Contact person for public queries
Name 150211 0
Cathy Liu
Address 150211 0
Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, 3052, VIC
Country 150211 0
Australia
Phone 150211 0
+61 0383453200
Fax 150211 0
Email 150211 0
Contact person for scientific queries
Name 150212 0
Cathy Liu
Address 150212 0
Royal Women's Hospital, 20 Flemington Road, Parkville, Melbourne, 3052, VIC
Country 150212 0
Australia
Phone 150212 0
+61 0383453200
Fax 150212 0
Email 150212 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.